Jillian Smith

3.2k total citations · 2 hit papers
16 papers, 2.2k citations indexed

About

Jillian Smith is a scholar working on Physiology, Neurology and Oncology. According to data from OpenAlex, Jillian Smith has authored 16 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Physiology, 4 papers in Neurology and 4 papers in Oncology. Recurrent topics in Jillian Smith's work include Alzheimer's disease research and treatments (6 papers), Cholinesterase and Neurodegenerative Diseases (3 papers) and Immune Cell Function and Interaction (3 papers). Jillian Smith is often cited by papers focused on Alzheimer's disease research and treatments (6 papers), Cholinesterase and Neurodegenerative Diseases (3 papers) and Immune Cell Function and Interaction (3 papers). Jillian Smith collaborates with scholars based in United States, United Kingdom and Switzerland. Jillian Smith's co-authors include Crystal L. Mackall, Rosandra N. Kaplan, Rimas J. Orentas, Adrienne H. Long, Alec J. Walker, Yongzhi Cui, Steven L. Highfill, M. Eric Kohler, Maria Ingaramo and Meera Murgai and has published in prestigious journals such as Nature Medicine, Neurology and The Lancet Neurology.

In The Last Decade

Jillian Smith

15 papers receiving 2.2k citations

Hit Papers

4-1BB costimulation ameliorates T cell exhaustion induced... 2014 2026 2018 2022 2015 2014 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
    2015 1.3k citations Adrienne H. Long, Waleed Haso et al. Nature Medicine profile →
  2. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
    2014 595 citations Steven L. Highfill, Yongzhi Cui et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jillian Smith United States 8 1.8k 1.1k 574 541 390 16 2.2k
John M. Rossi United States 22 2.1k 1.2× 654 0.6× 538 0.9× 815 1.5× 543 1.4× 84 2.6k
Dongrui Wang United States 17 1.4k 0.8× 688 0.7× 480 0.8× 688 1.3× 275 0.7× 39 1.9k
Jason Plotkin United States 8 1.6k 0.9× 778 0.7× 569 1.0× 603 1.1× 499 1.3× 8 2.0k
Carmen S. Yong Australia 12 1.2k 0.6× 848 0.8× 303 0.5× 455 0.8× 313 0.8× 21 1.7k
Karen S. Kelly‐Spratt United States 17 1.3k 0.7× 263 0.2× 297 0.5× 1.0k 1.9× 318 0.8× 24 2.0k
Victoria Casado‐Medrano United States 14 756 0.4× 392 0.4× 262 0.5× 469 0.9× 201 0.5× 22 1.1k
Kristen Fousek United States 11 703 0.4× 431 0.4× 198 0.3× 298 0.6× 122 0.3× 21 1.1k
Kevin Sek Australia 8 935 0.5× 749 0.7× 205 0.4× 419 0.8× 159 0.4× 11 1.3k
Linchun Jin United States 10 533 0.3× 336 0.3× 260 0.5× 378 0.7× 115 0.3× 18 1.1k

Countries citing papers authored by Jillian Smith

Since Specialization
Citations

This map shows the geographic impact of Jillian Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jillian Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jillian Smith more than expected).

Fields of papers citing papers by Jillian Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jillian Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jillian Smith. The network helps show where Jillian Smith may publish in the future.

Co-authorship network of co-authors of Jillian Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Jillian Smith. A scholar is included among the top collaborators of Jillian Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jillian Smith. Jillian Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Habib, Ali A., Chongbo Zhao, Inmaculada Aban, et al.. (2025). Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology. 24(2). 117–127. 10 indexed citations
2.
3.
Habib, Ali A., Chongbo Zhao, Inmaculada Aban, et al.. (2024). LUMINESCE, a Phase 3 Study of Satralizumab in Generalized Myasthenia Gravis (gMG): Baseline Characteristics (P10-11.015). Neurology. 102(7_supplement_1). 1 indexed citations
4.
Guthrie, Heather, Lawrence S. Honig, Helen Lin, et al.. (2020). Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks. Journal of Alzheimer s Disease. 76(3). 967–979. 41 indexed citations
5.
Sink, Kaycee M., Jillian Smith, Reina N. Fuji, et al.. (2019). P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 15(7S_Part_4). 2 indexed citations
6.
Sink, Kaycee M., Susanne Ostrowitzki, Helen Lin, et al.. (2019). Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD) (P4.1-002). Neurology. 92(15_supplement). 2 indexed citations
7.
Lin, Helen, Susanne Ostrowitzki, Kaycee M. Sink, et al.. (2018). O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD). Alzheimer s & Dementia. 14(7S_Part_4). 2 indexed citations
8.
Reiman, Eric M., Kaycee M. Sink, Nan Hu, et al.. (2018). P4‐209: A PUBLIC RESOURCE OF BASELINE DATA FROM THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL. Alzheimer s & Dementia. 14(7S_Part_29).
9.
Lin, Helen, Angelica Quartino, Tobias Bittner, et al.. (2018). Safety, Tolerability and Pharmacokinetics of Crenezumab in Mild-to-Moderate AD Patients Treated with Escalating Doses for up to 32.3 Months (P6.182). Neurology. 90(15_supplement). 3 indexed citations
10.
Asnaghi, Veronica, Helen Lin, Michael Rabbia, et al.. (2017). Long-Term Safety And Tolerability Of Escalating Doses Of Crenezumab In Patients With Mild-To-Moderate Alzheimer’s Disease (P6.083). Neurology. 88(16_supplement). 4 indexed citations
11.
Asnaghi, Veronica, Helen Lin, Nan Hu, et al.. (2017). [O2–17–06]: SAFETY AND TOLERABILITY OF CRENEZUMAB IN MILD‐TO‐MODERATE AD PATIENTS TREATED WITH ESCALATING DOSES FOR UP TO 25 MONTHS. Alzheimer s & Dementia. 13(7S_Part_12). 3 indexed citations
12.
Long, Adrienne H., Steven L. Highfill, Yongzhi Cui, et al.. (2016). Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunology Research. 4(10). 869–880. 258 indexed citations
13.
14.
Long, Adrienne H., Waleed Haso, Jack F. Shern, et al.. (2015). 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine. 21(6). 581–590. 1252 indexed citations breakdown →
15.
Highfill, Steven L., Yongzhi Cui, Amber Giles, et al.. (2014). Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy. Science Translational Medicine. 6(237). 237ra67–237ra67. 595 indexed citations breakdown →
16.
Phillips, Michael, et al.. (1995). Volatile organic compounds in the breath of patients with schizophrenia.. Journal of Clinical Pathology. 48(5). 466–469. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John M. Rossi Breakdown of academic impact, for papers by Dongrui Wang Breakdown of academic impact, for papers by Jason Plotkin Breakdown of academic impact, for papers by Carmen S. Yong Breakdown of academic impact, for papers by Karen S. Kelly‐Spratt Breakdown of academic impact, for papers by Victoria Casado‐Medrano Breakdown of academic impact, for papers by Kristen Fousek Breakdown of academic impact, for papers by Kevin Sek Breakdown of academic impact, for papers by Linchun Jin
Rankless by CCL
2026